The short answer is still no.
Updated August 15, 2026 to reflect the July PCAC vote.
On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 free base and BPC-157 acetate to the 503A Bulks List. The reported tally was 8 yes, 6 no, 1 abstain.[1]
That is the development everyone is reacting to, and it is genuinely significant. It is also not what most of the coverage implied. As of August 15, 2026, BPC-157 is not FDA-approved, is not an over-the-counter drug, has not been broadly legalized for consumer sale, and is not legal to compound. FDA has published no proposed rule, no Federal Register document, and no change to any bulks list since the vote.[8]
- A recommendation is not a rule. PCAC advises; FDA decides, through notice-and-comment rulemaking. FDA has not started.
- 503A is not OTC. Section 503A is a prescription compounding pathway for identified patients, not a retail shelf or supplement pathway.
- Compounding is not FDA approval. Even properly compounded drugs are not FDA-approved products.
- FDA's own reviewers said no. FDA's review team recommended against all seven peptides on the agenda. The committee voted the other way on six.
- The reviewed use matters. FDA's agenda lists ulcerative colitis as the evaluated use for BPC-157, not tendon repair, bodybuilding recovery, anti-aging, or general wellness.
Quick facts
- Current answer
- No — not legal to compound
- FDA-approved drug?
- No
- OTC access?
- No
- PCAC vote
- July 23, 2026 — recommended
- Reported tally
- 8 yes, 6 no, 1 abstain
- FDA action since
- None as of Aug 15, 2026
What actually changed
The committee answered a narrow question: should BPC-157-related bulk drug substances be placed on the 503A Bulks List? That list matters because 503A compounders can only use bulk drug substances that meet specific legal criteria: an applicable USP/NF monograph, a component of an FDA-approved drug product, or appearance on FDA's 503A bulks list when neither of the first two applies.[2]
The committee said yes. FDA has not.
That distinction is the whole story. A "yes" from PCAC does not create an FDA-approved BPC-157 drug. It does not make research-chemical vials, supplement-style capsules, or general wellness marketing lawful. And it does not, on its own, let a single compounding pharmacy in the country legally prepare BPC-157 from bulk.
Why a recommendation is not approval
FDA advisory committees exist to give expert advice. Their recommendations are not binding. FDA's own PCAC charter says the committee provides advice and recommendations while FDA retains regulatory decision-making authority.[4]
For BPC-157 to actually become compoundable, FDA would have to publish a proposed rule, take public comment, and issue a final rule. As of August 15, 2026 it has done none of those things — the most recent Federal Register action on the 503A Bulks List is still the April 16, 2026 notice that convened the meeting in the first place.[8]
There is one more reason not to treat the vote as a foregone conclusion. FDA's own scientists recommended against all seven peptides on the agenda. Its slides say of BPC-157: "FDA is proposing that BPC-157 (free base) and BPC-157 acetate NOT be included on the 503A Bulks List," and separately conclude that "BPC-157 acetate is not well-characterized."[7] An advisory committee overriding FDA staff is unusual, and it makes FDA's eventual response harder to predict, not easier.
Why 503A is not OTC
Section 503A is the traditional pharmacy compounding pathway. It is built around a licensed pharmacist or physician compounding a drug for an identified individual patient based on a valid prescription or prescriber notation that the compounded product is necessary for that patient.[6]
That is fundamentally different from:
- a product sitting on a retail shelf
- a supplement brand selling BPC-157 capsules directly to consumers
- a research-chemical site selling injectable vials labeled "not for human consumption"
- a clinic advertising BPC-157 as broadly proven for injury recovery or anti-aging
If BPC-157 is eventually added to the 503A Bulks List, the practical meaning would be a limited prescription compounding pathway, not open consumer sale.
Why compounding is not FDA approval
FDA-approved drugs go through a drug approval process in which FDA reviews evidence for safety, effectiveness, labeling, and manufacturing quality for a specific product and use.
Compounded drugs are different. FDA says compounded drugs are not FDA-approved, meaning FDA does not review them for safety, effectiveness, or quality before they are marketed.[3]
That distinction is the core of the BPC-157 confusion. A future compounding pathway would not mean:
- FDA has found BPC-157 safe and effective for tendon healing
- FDA has approved a branded BPC-157 product
- insurance coverage follows
- athletes can use it
- all routes, doses, combinations, or marketing claims are validated
It would only mean the relevant bulk substance can be used in compounding under the conditions of that pathway.
What remains unresolved
FDA still publishes a BPC-157 safety-risk summary noting potential immunogenicity risk for certain routes of administration, peptide-related impurity concerns, API characterization complexity, and limited safety-related information for proposed routes of administration.[5] Its July 2026 slides restate those concerns in more detail, including two distinct impurity classes and the observation that it had no information on the individual impurities or on impurity limits and testing.[7]
The human evidence base is also still thin. BPC-157 has extensive animal data, but only a small number of published human studies and no completed Phase II or Phase III trial. A compounding vote does not fill that evidence gap. Nothing about July 23 changed what we know about whether BPC-157 works.
The precise answer
If someone asks, "Does this mean BPC-157 is legal now?", the clean answer is:
No. An FDA advisory committee recommended BPC-157 for a narrow prescription compounding pathway, over the objection of FDA's own reviewers. FDA has not acted on that recommendation, so BPC-157 is not legal to compound. It is also not FDA-approved, not over the counter, not proven safe and effective, and not legal to sell directly to consumers as a general wellness product.
That wording is less exciting than "legal again," but it is the difference that matters.
There are four distinct steps here, and vendors have a strong incentive to blur them: committee recommended is not FDA proposed, which is not FDA finalized, which is not legal to compound. BPC-157 is at step one.
References
- [1]U.S. Food and Drug Administration. “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” 2026. Link
Official FDA meeting notice listing BPC-157 free base and BPC-157 acetate for July 23, 2026 discussion for potential inclusion on the 503A Bulks List.
- [2]U.S. Food and Drug Administration. “Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.” 2026. Link
FDA explanation of which bulk drug substances may be used by state-licensed 503A compounders and how Category 1, 2, and 3 interim policy lists work.
- [3]U.S. Food and Drug Administration. “Understanding the Risks of Compounded Drugs.” 2026. Link
FDA consumer guidance explaining that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
- [4]U.S. Food and Drug Administration. “Pharmacy Compounding Advisory Committee Charter.” 2026. Link
FDA charter stating that PCAC provides recommendations while FDA retains regulatory decision-making authority.
- [5]U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.” 2026. Link
FDA safety-risk summary for BPC-157, including immunogenicity, peptide-related impurities, API characterization complexity, and limited route-specific safety information.
- [6]U.S. Food and Drug Administration. “Section 503A of the Federal Food, Drug, and Cosmetic Act.” 2026. Link
Statutory text for traditional pharmacy compounding, including patient-specific prescription conditions and the 503A exemption structure.
- [7]U.S. Food and Drug Administration. “July 23, 2026 PCAC Meeting — FDA Presentations.” 2026. Link
FDA's own slide deck. States that BPC-157 acetate 'is not well-characterized' and that FDA proposed BPC-157 free base and acetate NOT be included on the 503A Bulks List. Also contains FDA's opening talk on conflated bulks and common-name challenges.
- [8]U.S. Food and Drug Administration. “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments.” Federal Register. 2026. Link
FR Doc. 2026-07361, published April 16, 2026; public docket FDA-2025-N-6895. As of August 15, 2026 this is still the most recent Federal Register action relating to the 503A Bulks List and these peptides — no proposed rule has followed the July vote.
The regulatory landscape is moving fast
Get notified when new regulatory changes affect peptide access. We track the FDA, so you don't have to.
Related content
BPC-157
Evidence, safety, and regulatory context for BPC-157.
NewsThe July 2026 PCAC Peptide Vote
Tallies, evaluated uses, and what FDA's own reviewers argued for all seven peptides.
ToolPeptide Legal Status Tracker
Source-checked status for every peptide we track, updated August 15, 2026.
NewsWhat Are Compounding Pharmacies?
How 503A and 503B pathways work, and why compounding is not FDA approval.
NewsFDA Peptide Categories Explained
A plain-language guide to FDA Category 1, 2, and 3 compounding lists.
Disclaimer
This article is for educational purposes only and does not constitute medical or legal advice. Regulatory status can change quickly. Verify current status through official FDA sources and consult a licensed professional before making health or legal decisions.